Results for tag: "Smith Lemli Opitz Syndrome Drug"

Smith-Lemli-Opitz Syndrome (SLOS) is a rare genetic disorder that affects the development of the central nervous system. It is caused by a deficiency in the enzyme 7-dehydrocholesterol reductase, which is responsible for the production of cholesterol. As a result, individuals with SLOS experience a range of physical and cognitive impairments, including intellectual disability, autism, and seizures. The SLOS drug market is focused on treatments that can improve the quality of life for those affected by the disorder. Currently, there are no approved drugs specifically for SLOS, but there are several medications that can be used to manage the symptoms. These include anticonvulsants, antipsychotics, and hormone replacement therapy. Additionally, research is ongoing to develop new treatments that can target the underlying cause of the disorder. Some companies in the SLOS drug market include AbbVie, Pfizer, and Merck. These companies are actively researching and developing new treatments for SLOS, as well as providing existing medications to manage the symptoms. Show Less Read more